Allena Stock Analysis

ALNA
 Stock
  

USD 0.0112  0.0013  10.40%   

The big decline in price over the last few months for Allena Pharmaceuticals could raise concerns from investors as the firm is trading at a share price of 0.0112 on very low momentum in volume. The company executives failed to add value to investors and position the firm supply of money to exploit market volatility in October. However, diversifying your holdings with Allena Pharmaceuticals or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 9.53. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Allena Pharmaceuticals partners.
Please continue to Trending Equities.
  
The Allena Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Allena Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Allena Stock analysis module also helps to analyze the Allena Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Allena Stock Analysis Notes

The company has price-to-book (P/B) ratio of 0.17. Some equities with similar Price to Book (P/B) outperform the market in the long run. Allena Pharmaceuticals recorded a loss per share of 1.01. The entity had not issued any dividends in recent years. Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. Allena Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NMS Exchange. It employs 17 people. For more info on Allena Pharmaceuticals please contact Alexey Margolin at 617 467-4577 or go to www.allenapharma.com.

Allena Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Allena Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Allena Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Allena Pharmaceuticals is not yet fully synchronised with the market data
Allena Pharmaceuticals generated a negative expected return over the last 90 days
Allena Pharmaceuticals has high historical volatility and very poor performance
Allena Pharmaceuticals has some characteristics of a very speculative penny stock
Allena Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (48.84 M).
Allena Pharmaceuticals currently holds about 8.89 M in cash with (55.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Allena Pharmaceuticals has a frail financial position based on the latest SEC disclosures

Allena Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Allena Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Allena Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report8th of March 2022
Next Financial Report10th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End8th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Allena Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Allena Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Allena Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Allena Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
2nd of September 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Bankruptcy or Receivership. Termination of a Material Definitive Agreement
View
24th of August 2022
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
View
11th of August 2022
Financial Statements and Exhibits. Other Events
View
4th of August 2022
Submission of Matters to a Vote of Security Holders
View
12th of July 2022
Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Completion of Acquisition or Disposition of Assets
View
11th of July 2022
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
8th of July 2022
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
View
5th of July 2022
Financial Statements and Exhibits. Other Events
View

Allena Market Capitalization

The company currently falls under 'Nano-Cap' category with current market capitalization of 6.4 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Allena Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Allena Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Allena Profitablity

Allena Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Allena Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Allena Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Allena Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Allena Pharmaceuticals' profitability requires more research than a typical breakdown of Allena Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(132.08) (142.50) 
Return on Average Equity(234.88) (253.42) 
Return on Invested Capital(9.55) (9.80) 

Management Efficiency

The entity has return on total asset (ROA) of (96.04) % which means that it has lost $96.04 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (278.14) %, meaning that it created substantial loss on money invested by shareholders. Allena Pharmaceuticals management efficiency ratios could be used to measure how well allena pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of November 27, 2022, Return on Average Assets is expected to decline to -142.5. In addition to that, Return on Average Equity is expected to decline to -253.42. Allena Pharmaceuticals Total Assets are projected to decrease significantly based on the last few years of reporting. The past year's Total Assets were at 34.76 Million. The current year Current Assets is expected to grow to about 49 M, whereas Assets Non Current are forecasted to decline to about 1.4 M.
Last ReportedProjected for 2022
Book Value per Share 0.28  0.30 
Enterprise Value over EBIT(1.15) (1.24) 
Enterprise Value over EBITDA(0.40) (0.43) 
Price to Book Value 2.59  2.91 
Tangible Assets Book Value per Share 0.51  0.53 
Enterprise Value19 M19.5 M
Tangible Asset Value34.8 M41.7 M

Allena Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Allena Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Allena Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Allena Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Allena Pharmaceuticals Technical and Predictive Indicators

About Allena Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Allena Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Allena shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Allena Pharmaceuticals. By using and applying Allena Stock analysis, traders can create a robust methodology for identifying Allena entry and exit points for their positions.
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. Allena Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NMS Exchange. It employs 17 people.

Current Allena Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Allena analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Allena analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
5.06Strong Buy4Odds
Allena Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Allena analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Allena stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Allena Pharmaceuticals, talking to its executives and customers, or listening to Allena conference calls.
Allena Analyst Advice Details

Allena Stock Analysis Indicators

Allena Pharmaceuticals stock analysis indicators help investors evaluate how Allena Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Allena Pharmaceuticals shares will generate the highest return on investment. By understating and applying Allena Pharmaceuticals stock analysis, traders can identify Allena Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio0.88
Fifty Two Week Low0.0153
Shares Short Prior Month2.56M
Average Daily Volume Last 10 Day43.01M
Average Daily Volume In Three Month31.46M
Shares Percent Shares Out7.97%
Short Percent Of Float8.06%
Forward Price Earnings-0.25
Float Shares106.61M
Fifty Two Week High1.1700
Enterprise Value To Ebitda-0.18
Fifty Day Average0.1135
Two Hundred Day Average0.2671
Please continue to Trending Equities. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for analysis

When running Allena Pharmaceuticals price analysis, check to measure Allena Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allena Pharmaceuticals is operating at the current time. Most of Allena Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Allena Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Allena Pharmaceuticals' price. Additionally, you may evaluate how the addition of Allena Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Is Allena Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allena Pharmaceuticals. If investors know Allena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allena Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
9.2 M
Return On Assets
(1.07) 
Return On Equity
(5.41) 
The market value of Allena Pharmaceuticals is measured differently than its book value, which is the value of Allena that is recorded on the company's balance sheet. Investors also form their own opinion of Allena Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Allena Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allena Pharmaceuticals' market value can be influenced by many factors that don't directly affect Allena Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allena Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Allena Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allena Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.